Bicara Therapeutics (BCAX) closed at $10.53 on November 11, 2026, up 3.4% from the previous close, on volume of 1,430,151 shares (30-day average 1,638,463).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 20, 2026 | Straddle or Synthetic | 18-Dec-2620 C : 20 P | 600 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
Analysts Are Bullish on These NA Stocks: Bicara Therapeutics Inc. (BCAX), Csquare, Inc. (CSQR)
TipRanks (Tue, 10-Nov 7:40 AM ET)
TipRanks (Tue, 10-Nov 6:40 AM ET)
Bank of America Securities Remains a Buy on Bicara Therapeutics Inc. (BCAX)
TipRanks (Tue, 10-Nov 6:05 AM ET)
Bicara’s Clinical Progress and Upcoming Catalysts Support Buy Rating; Price Target Unchanged at $30
TipRanks (Mon, 9-Nov 2:55 PM ET)
Bicara Therapeutics GAAP EPS of -$1.04 misses by $0.22
Seeking Alpha News (Mon, 9-Nov 7:46 AM ET)
Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Mon, 9-Nov 7:30 AM ET)
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Wed, 4-Nov 8:30 AM ET)
Globe Newswire (Mon, 2-Nov 8:30 AM ET)
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 14-Aug 8:30 AM ET)
Globe Newswire (Tue, 11-Aug 7:30 AM ET)
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
Bicara Therapeutics trades on the NASDAQ stock market under the symbol BCAX.
As of November 11, 2026, BCAX stock price climbed to $10.53 with 1,430,151 million shares trading.
BCAX has a beta of 1.26, meaning it tends to be more sensitive to market movements. BCAX has a correlation of 0.04 to the broad based SPY ETF.
BCAX has a market cap of $699.06 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that BCAX belongs to (by Net Assets): VTI, IWM, XBI, VXF, VTWO.
BCAX has underperformed the market in the last year with a price return of -24.4% while the SPY ETF gained +12.6%. BCAX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -62.0% and -39.8%, respectively, while the SPY returned -1.5% and -1.3%, respectively.
BCAX support price is $9.66 and resistance is $10.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCAX shares will trade within this expected range on the day.
